Kanvas Biosciences
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
$48MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
Provides advanced biosynthesis for pharmaceutical manufacturing and innovation
Pitching ATHOS KG? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room